Phase I and pharmacokinetics study of a novel anti-CD20 antibody, RO5072759 (GA101), in Japanese patients (Pts) with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) pretreated with rituximab.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. e18552-e18552
Author(s):  
K. Tobinai ◽  
M. Ogura ◽  
K. Hatake ◽  
Y. Kobayashi ◽  
M. Mori ◽  
...  
Keyword(s):  
Phase I ◽  
B Cell ◽  
Hodgkin Lymphoma ◽  
Japanese Patients ◽  
Non Hodgkin Lymphoma ◽  
Pharmacokinetics Study ◽  
Cd20 Antibody ◽  
Anti Cd20

A phase I trial of ublituximab (TG-1101), a novel glycoengineered anti-CD20 monoclonal antibody (mAb) in B-cell non-Hodgkin lymphoma patients with prior exposure to rituximab.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 8524-8524 ◽  
Author(s):  
Owen A. O'Connor ◽  
Changchun Deng ◽  
Jennifer Effie Amengual ◽  
Mazen Y. Khalil ◽  
Marshall T. Schreeder ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Phase I ◽  
B Cell ◽  
Hodgkin Lymphoma ◽  
Phase I Trial ◽  
Prior Exposure ◽  
Non Hodgkin Lymphoma ◽  
Anti Cd20

scholarly journals Phase I study of obinutuzumab (GA101) in Japanese patients with relapsed or refractory B-cell non-Hodgkin lymphoma

2012 ◽  
Vol 104 (1) ◽  
pp. 105-110 ◽  
Author(s):  
Michinori Ogura ◽  
Kensei Tobinai ◽  
Kiyohiko Hatake ◽  
Toshiki Uchida ◽  
Tatsuya Suzuki ◽  
...  
Keyword(s):  
Phase I ◽  
B Cell ◽  
Hodgkin Lymphoma ◽  
Phase I Study ◽  
Japanese Patients ◽  
Non Hodgkin Lymphoma

A phase I pharmacokinetic and safety study of polatuzumab vedotin in Japanese patients with relapsed/refractory b-cell non-Hodgkin lymphoma: A comparison with non-Japanese DCS4968g study.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. e19070-e19070 ◽  
Author(s):  
Kiyohiko Hatake ◽  
Tomohiro Kinoshita ◽  
Yasuhito Terui ◽  
Masahiro Yokoyama ◽  
Dai Maruyama ◽  
...  
Keyword(s):  
Phase I ◽  
B Cell ◽  
Hodgkin Lymphoma ◽  
Japanese Patients ◽  
Safety Study ◽  
Non Hodgkin Lymphoma

Safety and efficacy of anti-CD20 immunotoxin MT-3724 in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) in a phase I study.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. 7580-7580 ◽  
Author(s):  
Michelle A. Fanale ◽  
Paul A. Hamlin ◽  
Steven I. Park ◽  
Daniel Oscar Persky ◽  
Jack P. Higgins ◽  
...  
Keyword(s):  
Phase I ◽  
B Cell ◽  
Hodgkin Lymphoma ◽  
Phase I Study ◽  
Safety And Efficacy ◽  
Non Hodgkin Lymphoma ◽  
Anti Cd20

scholarly journals CD20 antibodies: type II to tango?

Blood ◽  
2012 ◽  
Vol 119 (22) ◽  
pp. 5061-5063 ◽  
Author(s):  
Marinus H. J. van Oers
Keyword(s):  
Monoclonal Antibody ◽  
B Cell ◽  
Hodgkin Lymphoma ◽  
Type Ii ◽  
Non Hodgkin Lymphoma ◽  
Anti Cd20 ◽  
Intense Research ◽  
Cd20 Antibodies

Although the chimeric anti-CD20 monoclonal antibody (mAb) rituximab has revolutionized the treatment of B-cell non-Hodgkin lymphoma (NHL), still many patients relapse and an increasing number become refractory to rituximab-containing therapy. This has initiated intense research to develop more potent anti-CD20 antibodies.

Sign in / Sign up

Export Citation Format

Share Document